Historically, 5-year PFS for PTCL (excluding non ALK-positive ALCL) is approximately 20% and up to 30% of patients may be primary refractory [19, 20]. This evidence concerns the gene ALK and mature T-cell and NK-cell non-Hodgkin lymphoma.